Volume | 1,837 |
|
|||||
News | - | ||||||
Day High | 1.34 | Low High |
|||||
Day Low | 1.28 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Protagenic Therapeutics Inc | PTIX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.34 | 1.28 | 1.34 | 1.28 | 1.375 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
27 | 1,837 | $ 1.30 | $ 2,383 | - | 0.6797 - 2.32 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:00:00 | 86 | $ 1.29 | USD |
Protagenic Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
5.68M | 4.44M | - | 0 | -5M | -1.13 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Protagenic Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical PTIX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.45 | 1.48 | 1.25 | 1.38 | 4,231 | -0.17 | -11.72% |
1 Month | 1.59 | 1.80 | 1.1535 | 1.52 | 9,458 | -0.31 | -19.50% |
3 Months | 0.9359 | 1.87 | 0.87 | 1.33 | 12,679 | 0.3441 | 36.77% |
6 Months | 0.77 | 1.87 | 0.6797 | 1.17 | 9,189 | 0.51 | 66.23% |
1 Year | 1.89 | 2.32 | 0.6797 | 1.29 | 8,979 | -0.61 | -32.28% |
3 Years | 9.12 | 19.56 | 0.6797 | 11.30 | 436,781 | -7.84 | -85.96% |
5 Years | 11.00 | 19.56 | 0.6797 | 11.27 | 440,762 | -9.72 | -88.36% |
Protagenic Therapeutics Description
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression and neurodegenerative disorders by using peptide-based and brain active therapeutics. The company's lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders. |